Disease index

spasticity post-stroke

Neurology · 2007–2019

5decisions
3medicines
0carried consumer input
0individual submissions

No submission for this condition has carried consumer input, including the one made since the comments facility came into use.

Every decision

MedicineMeetingOutcomeConsumer input
Clostridium botulinum type A toxin – haemagglutinin complex Treatment of moderate to severe spasticity of the lower limb following stroke or other acute neurological events. Jul 2019 Recommended with restriction none received
Botulinum toxin type A purified neurotoxin complex Treatment of moderate to severe spasticity of the lower limb in ambulatory adults following a stroke as second line therapy when standard management has failed… Jul 2008 Not recommended no section in document
botulinum toxin type a purified neurotoxin complex Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a… Jul 2008 Recommended with restriction no section in document
clostridium botulinum type A toxin-haemagglutinin complex Treatment of moderate to severe spasticity of the upper limb in adults following a stroke (defined as Modified Ashworth Scale score ≥2 in at least 2 joints),… Nov 2007 Recommended with restriction no section in document
clostridium botulinum type A toxin-haemagglutinin complex Treatment of moderate to severe spasticity of the upper limb in adults following a stroke, as second line therapy when standard management has failed or as an… Nov 2007 Recommended with restriction no section in document

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.